- Company
- Esophageal cancer, added to indication of Opdivo·Keytruda
- by Eo, Yun-Ho Mar 22, 2022 05:53am
- Cancer immunotherapys are advancing into the esophageal cancer area one after another. According to related industries, Opdivo (Nivolumab) and MSD's Keytruda recently were added esophageal cancer indications in Korea. Opdivo obtained final approval from the MFDS last month and Keytruda on the 7th. With this permission, Opdivo can be prescribe
- Company
- Celltrion was fined 13.9 billion won
- by Kim, Jin-Gu Mar 22, 2022 05:53am
- Financial authorities imposed a fine of 13.9 billion won on three Celltrion companies that prepared and disclosed financial statements in violation of accounting standards. The Financial Services Commission held its fifth regular meeting on the 16th and decided on this. The fines decided at the meeting are 6 billion won for Celltrion, 6.04
- Company
- Concerns over fungal infection due to COVID-19
- by Eo, Yun-Ho Mar 21, 2022 05:56am
- There is concern about the gap in fungal infections due to the re-proliferation of COVID-19. The most commonly reported fungal infections in COVID-19 patients include COVID-19 associated pulmonic aspergillosis (CAPA), COVID-19 associated mucomycosis (CAM), and Candida auris. These COVID-19-related fungal infections can lead to serious dise
- Company
- 5 companies challenge breast cancer drug Ibrance’s patent
- by Kim, Jin-Gu Mar 21, 2022 05:55am
- The number of companies challenging the patent of Pfizer’s breast cancer treatment ‘Ibrance (palbociclib)’ has increased to 5. According to the pharmaceutical industry, Boryung Pharmaceutical, Shinpoong Pharm, Daewoong Pharmaceutical, and Samyang Holdings had filed a series of claims to confirm the passive scope of rights on Ibrance’
- Company
- K-Bio has become a global production hub
- by Kim, Jin-Gu Mar 18, 2022 05:55am
- The Korean pharmaceutical bio industry has become a global coronavirus vaccine and treatment consignment production hub. With the consignment production of coronavirus vaccines and antibody treatments in charge, the company will be in charge of consignment production of oral treatments for the supply of underdeveloped countries. On the 17t
- Company
- Largest shareholder of Medipost changed to a private equity
- by Chon, Seung-Hyun Mar 18, 2022 05:55am
- The largest shareholder of the bio venture company Medipost will be changed from the founder and CEO Yoon-sun Yang to a private equity consortium. Medipost plans to receive an investment of approximately &8361;140 billion from a private equity fund to invest in its cell and gene therapy business. On the 17th, Medipost announced that it h
- Company
- Multinational pharmaceutical companies are changing logos
- by Mar 18, 2022 05:55am
- Organon Korea returns after 13 years of absence with a new logo, "Women's Health" starts anew. Multinational pharmaceutical companies are trying to transform their image with new logos. Pfizer entered the unexplored area of mRNA and changed its logo in about 70 years. Sanofi also emphasized "one Sanofi" as an integrated brand logo. Analysts s
- Company
- Same ‘one-shot’ but different? Zolgensma reimb slow
- by Eo, Yun-Ho Mar 17, 2022 05:59am
- Although both drugs are from the same pharmaceutical company and are both one-shot, high-priced drugs, the two drugs are showing a stark difference in their results. Discussions on the reimbursement listing for Novartis Korea’s Zolgensma (onasemnogene abeparvovec) is not progressing so smoothly. The company had applied for the reimbursem
- Company
- Molnupiravir can be supplied on the day of approval
- by Mar 17, 2022 05:58am
- MSD is trying to contribute a lot to overcoming the COVID-19 pandemic. Molnupiravir is fully prepared to be supplied on the same day as soon as it is approved. Kevin Peters, CEO of MSD Korea, made the remarks at a press conference held on the 16th. MSD developed the COVID-19 treatment Molnupiravir last year and received the U.S. Food and
- Company
- Verzenio makes "bid with verified data” against Ibrance
- by Mar 17, 2022 05:58am
- The breast cancer treatment ‘Verzenio’ is working hard to expand its market. Although it is a latecomer in the CDK 4/6 inhibitor market, Lilly is showing confidence that it can bring different results from other previous treatments. In fact, Verzenio is pioneering the base of use of CDK4/6 inhibitors from metastatic breast cancer to early b
